WILMINGTON, Mass.--(BUSINESS WIRE)--Cellceutix (OTCBB: CTIX) President and CSO Dr. Krishna Menon, lead developer of Eli Lilly (NYSE: LLY) cancer compounds Gemzar® and Alimta®, recently conducted a pooled analysis of animal tests of Cellceutix’s lead candidate, Kevetrin™, against Head and Neck cancer SCC-15, a squamous cell carcinoma. The results demonstrated that compared with controls, Kevetrin as solo treatment produced tumor reduction of 31.5% and when administered sequentially with radiation produced tumor reduction of 73.7%. The results offer hope against the sixth most common cancer globally, but one that headlines few pipelines.
